Mingzhu Li

Dr. Mingzhu Li

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2022 in Viruses
Verified
Journal Article
Open access
PDF file
Jianming TangJianming Tang
Jianming Tang
MLMingzhu Li
Mingzhu Li
CZChao Zhao
Chao Zhao
DSDanhua Shen
Danhua Shen
LLLei Liu
Lei Liu
Lihui WeiLihui Wei
Lihui Wei
In 2014 and 2021, two nucleic-acid vaccine candidates named MAV E2 and VGX-3100 completed phase III clinical trials in Mexico and U.S., respectively, for patients with human papillomavirus (HPV)-related, high-grade squamous intraepithelial lesions (HSIL). These well-tolerated but still unlicensed vaccines encode distinct HPV antigens (E2 versus E6+E7) to elicit cell-mediated immune responses; their clinical efficacy, as measured by HSIL regression or cure, was modest when compared with placebo or surgery (conization), but both proved highly effective in clearing HPV infection, which should help further optimize strategies for enhancing vaccine immunogenicity, toward an ultimate goal of preventing malignancies in millions of patients who are living with persistent, oncogenic HPV infection but are not expected to benefit from current, prophylactic vaccines. The major roadblocks to a highly efficacious and practical product remain challenging and can be classified into five categories: (i) getting the vaccines into the right cells for efficient expression and presentation of HPV antigens (fusion proteins or epitopes); (ii) having adequate coverage of oncogenic HPV types, beyond the current focus on HPV-16 and -18; (iii) directing immune protection to various epithelial niches, especially anogenital mucosa and upper aerodigestive tract where HPV-transformed cells wreak havoc; (iv) establishing the time window and vaccination regimen, including dosage, interval and even combination therapy, for achieving maximum efficacy; and (v) validating therapeutic efficacy in patients with poor prognosis because of advanced, recurrent or non-resectable malignancies. Overall, the room for improvements is still large enough that continuing efforts for research and development will very likely extend into the next decade.

7 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MLMingzhu Li
Mingzhu Li
CZChao Zhao
Chao Zhao
XZXiaobo Zhang
Xiaobo Zhang
JLJingran Li
Jingran Li
YZYun Zhao
Yun Zhao
Lihui WeiLihui Wei
Lihui Wei
The relationship of PAX1/JAM3 methylation as well as HPV viral load (VL) with cervical lesions has been reported, but their role in persistent HPV infection without cervical high-grade lesions has not been fully elucidated. A total of 231 females diagnosed with persistent HPV infection and pathologically confirmed absence of high-grade cervical lesions were selected from the Colposcopy Outpatient Clinic of Peking University People’s Hospital, from March 2023 to December 2023. They were categorized into two groups based on the duration of HPV infection: the HPV persistent less than 3 years group and the more than 3 years group. PAX1/JAM3 methylation and HPV VL were determined by real-time PCR and BioPerfectus Multiplex Real-Time (BMRT)-HPV reports type-specific VL/10,000 cells, respectively. The average age of individuals with HPV infection lasting more than 3 years was higher compared to those with less than 3 years (48.9 vs. 45.1 years), with a statistically significant difference. Among the participants, 81.8% (189/231) had no previous screening. The methylation levels of JAM3 and PAX1 were significantly higher in individuals with HPV infection persisting for more than 3 years compared to those with less than 3 years, with a statistically significant difference (p < 0.05). There was a significant correlation between PAX1 and JAM3 methylation (p < 0.001), which could be used as cumulative evidence of HPV infection duration before the occurrence of precancerous lesions. The incidence of vaginal intraepithelial lesions was higher in individuals with HPV infection persisting for more than 3 years compared to those with less than 3 years, and HPV VL can be used as an indicative biomarker for concurrent cervical–vaginal lesions, especially for HPV other than 16/18 genotypes.

27 July 2022 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
MLMingzhu Li
Mingzhu Li
CZChao Zhao
Chao Zhao
YZYun Zhao
Yun Zhao
JLJingran Li
Jingran Li
Lihui WeiLihui Wei
Lihui Wei
Objective. This study evaluated the distribution of vaginal microbiota dysbiosis and the association with HPV viral load test in high-risk HPV-positive women before and after 50 years old. Methods. For this cross-sectional study, 388 HPV-positive women prior to referral to colposcopy in Peking University Peoples’ Hospital were included and classified as younger than 50 years ( ) and aged 50 years or older ( ), midvagina bacterial community composition was characterized by FlashDetect™ MAX vaginal microbe detection kit, and BMRT-HPV reported type-specific viral loads/10,000 cells. Results. The community state type (CST) IV was the most common CST occurring in 148 women (38.1%). The proportion of CST IV in those aged 50 years or older was significantly higher than those younger than 50 years (women) (66.7% vs. 30.6%); the difference was statistically significant (<0.001). CST distribution has no statistical difference in different grades of cervical lesion, regardless of the age ( and 0.263). However, the women with high-grade cervical lesion presented a more complicated trend and the abundance of vaginal microbiota dysbiosis than low-grade lesion. HPV16/18 viral load was found to be significantly higher in CST III and CST IV than CST I/II/V ( ) in women younger than 50 years. Conclusions. In women younger than 50 years, higher HPV16/18 load was more closely associated with CST IV; however, it had no significant correlation in women aged 50 years or older.

27 May 2025 in Gynecology and Obstetrics Clinical Medicine
Verified
Journal Article
Open access
PDF file
MLMingzhu Li
Mingzhu Li
JLJingran Li
Jingran Li
XLXiao Li
Xiao Li
XWXinyu Wang
Xinyu Wang
LKLinghua Kong
Linghua Kong
Lihui WeiLihui Wei
Lihui Wei
Cervical cancer is a common malignant tumour that has become a major global public health issue, seriously threatening women’s lives. In November 2020, the WHO released a global strategy to accelerate the elimination of cervical cancer as a public health problem. So far, the proposal has received positive responses and commitments from 194 countries around the world, including China, which has actively promoted the prevention and treatment of cervical cancer nationwide. In support of the WHO initiative, in January 2023, the Chinese National Health Commission, along with other entities, issued a 7-year Action Plan for Accelerating the Elimination of Cervical Cancer (2023–2030), which primarily focused on improving the cervical cancer prevention and control service system and on strengthening its overall capacity. Furthermore, based on research evidence and practical experience, experts from seven Chinese academic societies—including the Chinese Society for Colposcopy and Cervical Pathology of China Healthy Birth Science Association and Chinese Society of Gynecological Oncology, Chinese Medical Association—have recently published the Guidelines for cervical cancer screening in China II (Guideline II). Unlike the previous Guidelines for cervical cancer screening in China I (Guideline I),1 which primarily focused on primary screening methods for cervical cancer, Guideline II emphasises the management and triage of abnormal primary screening results. As part of tertiary prevention, both screening and triage are critical steps in preventing the progression of cervical cancer, especially for those with abnormal test results. Here, we present a new guideline focused on standardising the triage of abnormal cervical cancer screening to improve management, reduce missed diagnoses and prevent overdiagnosis.

17 June 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
MLMingzhu Li
Mingzhu Li
LLLei Liu
Lei Liu
XLXiaoli Li
Xiaoli Li
JLJingran Li
Jingran Li
CZChao Zhao
Chao Zhao
Lihui WeiLihui Wei
Lihui Wei
Therapeutic HPV vaccines that induce potent HPV-specific cellular immunity and eliminate pre-existing infections remain elusive. Among various candidates under development, those based on DNA constructs are considered promising because of their safety profile, stability, and efficacy. However, the use of electroporation (EP) as a main delivery method for such vaccines is notorious for adverse effects like pain and potentially irreversible muscle damage. Moreover, the requirement for specialized equipment adds to the complexity and cost of clinical applications. As an alternative to EP, lipid nanoparticles (LNPs) that are already commercially available for delivering mRNA and siRNA vaccines are likely to be feasible. Here, we have compared three intramuscular delivery systems in a preclinical setting. In terms of HPV-specific cellular immune responses, mice receiving therapeutic HPV DNA vaccines encapsulated with LNP demonstrated superior outcomes when compared to EP administration, while the naked plasmid vaccine showed negligible responses, as expected. In addition, SM-102 LNP M exhibited the most promising results in delivering candidate DNA vaccines. Thus, LNP proves to be a feasible delivery method in vivo, offering improved immunogenicity over traditional approaches.

30 December 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
MLMingzhu Li
Mingzhu Li
CZChao Zhao
Chao Zhao
YZYun Zhao
Yun Zhao
JLJingran Li
Jingran Li
XZXiaobo Zhang
Xiaobo Zhang
Lihui WeiLihui Wei
Lihui Wei
Background: PAX1 methylation (PAX1m) and HPV viral load (VL) have been reported to detect cervical high-grade squamous intraepithelial lesions (HSIL), but the relationship between them is unclear. This study aimed to evaluate the correlation between HPV VL and PAX1m and its effectiveness in predicting cervical lesions. (2) Methods: A total of 476 women referred to colposcopy for abnormal cervical screening at the Peking University People’s Hospital between November 2020 and November 2021 were enrolled. PAX1m and HPV VL were determined by QMSP and BMRT-HPV reports type-specific VL/10,000 cells, respectively. (3) Results: PAX1m was significantly increased in HSIL, especially in cervical cancer, but there was no significant difference between cervical intraepithelial neoplasms 1(CIN1) and CIN2. However, HPV VL significantly differed between CIN1 and CIN2 but not between CIN3 and cervical cancer. In general, PAX1m positively correlated with all hrHPV VL, mainly in the HPV16/18 VL (p < 0.001), but had no relationship with the other 12 types of hrHPV VL. PAX1m had the highest specificity in diagnosing CIN2+, followed by HPV16/18 VL, which are higher than cytology ≥ASCUS. (4) Conclusions: Hypermethylation of PAX1 is associated with high HPV VL, especially HPV16/18, and both present advantageous specificity in detecting CIN2+.